Abstract
The aim of this study was to determine the influence of thrombocytopenia during HT as a prognostic factor in patients with non-small cell lung cancer (NSCLC). The study was non-randomized, retrospective–prospective and conducted in the Institute for pulmonary diseases in Sremska Kamenica. The study included 100 NSCLC patients, clinical stages III and IV, who were treated with protocol gemcitabine/cisplatin in first line setting. Study group consisted of 50 patients with, and control group of 50 patients without hematological toxicity during HT. Survival was monitored in a prospective two-year period.
There were 76% males and 24% females in the sample. The most frequent were patients in stage IV (52%), and the most common histological type was adenocarcinoma (47%). The initial value of platelets did not affect the occurrence of thrombocytopenia all grades during HT (p<0.72), while the starting thrombocytosis was a negative prognostic factor (p<0.012). All grades of thrombocytopenia, together, had prognostic significance (p<0.025), while multivariate analysis has not been established that thrombocytopenia is independent prognostic factor (p<0.683). Patients with thrombocytopenia grades 3 and 4 had statistically significant better survival in regard to patients with thrombocytopenia grades 0, 1 and 2 (p<0.03, p<0.01, p<0.02).
Conclusion: thrombocytopenia is not an independent prognostic factor, but patients with higher grades of thrombocytopenia had better survival.
- Copyright ©the authors 2016